TY  - JOUR
A1  - Durán Mejía, Verónica
A1  - Grabski, Elena
A1  - Hozsa, Constantin
A1  - Becker, Jennifer
A1  - Yasar, Hanzey
A1  - Monteiro, João T.
A1  - Costa, Bibiana
A1  - Koller, Nicole
A1  - Lueder, Yvonne
A1  - Wiegmann, Bettina Pamela
A1  - Brandes, Gudrun
A1  - Kaever, Volkhard
A1  - Lehr, Claus-Michael
A1  - Lepenies, Bernd
A1  - Tampé, Robert
A1  - Förster, Reinhold
A1  - Bošnjak, Berislav
A1  - Furch, Marcus
A1  - Graalmann, Theresa
A1  - Kalinke, Ulrich
T1  - Fucosylated lipid nanocarriers loaded with antibiotics efficiently inhibit mycobacterial propagation in human myeloid cells
T2  - Journal of controlled release
N2  - Antibiotic treatment of tuberculosis (TB) is complex, lengthy, and can be associated with various adverse effects. As a result, patient compliance often is poor, thus further enhancing the risk of selecting multi-drug resistant bacteria. Macrophage mannose receptor (MMR)-positive alveolar macrophages (AM) constitute a niche in which Mycobacterium tuberculosis replicates and survives. Therefore, we encapsulated levofloxacin in lipid nanocarriers functionalized with fucosyl residues that interact with the MMR. Indeed, such nanocarriers preferentially targeted
MMR-positive myeloid cells, and in particular, AM. Intracellularly, fucosylated lipid nanocarriers favorably delivered their payload into endosomal compartments, where mycobacteria reside. In an in vitro setting using infected human primary macrophages as well as dendritic cells, the encapsulated antibiotic cleared the pathogen more efficiently than free levofloxacin. In conclusion, our results point towards carbohydrate-functionalized nanocarriers as a promising tool for improving TB treatment by targeted delivery of antibiotics.
KW  - Tuberculosis
KW  - Alveolar macrophages
KW  - Targeted drug delivery
KW  - Liposomes
KW  - Nanomedicine
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/63091
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-630919
SN  - 1873-4995
VL  - 334
SP  - 201
EP  - 212
PB  - Elsevier
CY  - New York, NY [u.a.]
ER  -